Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect

US7361638B2 · kind B2 · utility

Assignee

• CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA · CU

Inventors

• Jorge Amador Berlanga Acosta · Boyeros, CU
• Gerardo Enrique Guillen Nieto · Boyeros, CU
• Diana Garcia Del Barco Herrera · Boyeros, CU
• Julio Raul Fernandez Masso · Boyeros, CU
• Mario Pablo Estrada Garcia · Boyeros, CU
• Isabel Guillen Perez · Boyeros, CU
• Jose Suarez Alba · Boyeros, CU
• Rebeca Martinez Rodriguez · Boyeros, CU

Key dates

• Filing date: Dec 17, 2001
• Grant date: Apr 22, 2008
• Expiry date: Jun 25, 2023

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to a medicine for humans, and particularly to a pharmaceutical combination comprising Epidermal Growth Factor (EGF) and Growth Hormone secretagogue hexapeptide (GHRP) for use in preventing tissue damage due to blood flow suppression by enhancing tissue repair following ischemic damage. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is also useful in promoting cellular survival when tissue or organs are exposed to prolonged ischemic periods. The combination is useful as a prophylactic agent in those subjects prone to multiple organ failure (MOF) such as burn victims, multiple trauma patients, hypoxic neonates, acute respiratory distress syndrome patients, and necrotizing enterocolitis patients.